Potomac Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Off-label use of multiple drugs has become a widespread clinical practice in treating schizophrenia. Potomac Pharma Inc. aims to improve outcomes by developing a highly selective alpha-2 antagonists for adjunctive use in treating neurological and psychiatric disorders.